Lexicon Pharmaceuticals
Yahoo Finance • 11 months ago
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
Over the long run, Wall Street has proved to be a surefire wealth creator. But over shorter periods, the performance of the major stock indexes is unpredictable. Since this decade began, the Dow Jones Industrial Average, S&P 500, and Nasda... Full story
Yahoo Finance • 11 months ago
3 of the Fastest-Growing Stocks on the Planet in 2024
Although it's been an adventurous couple of years for investors, 2023 turned out to be a phenomenal year for the bulls. The Dow Jones Industrial Average climbed to a fresh all-time high, while the S&P 500 and Nasdaq Composite respectively... Full story
Yahoo Finance • 12 months ago
7 Magnificent Stocks That Can Double Your Money in 2024
What a difference a year can make on Wall Street. After enduring two bear markets in less than three years, all three major indexes soared in 2023. The iconic Dow Jones Industrial Average climbed to a record high, while the broad-based S&P... Full story
Yahoo Finance • 12 months ago
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
Ascending Bar Chart Line Invest Financial Newspaper Stock Market Quote Rally Bull Getty In less than a week, Wall Street will turn the page on what's been a stellar year for optimists. The 30-component Dow Jones Industrial Average climbed... Full story
Yahoo Finance • last year
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has prev... Full story
Yahoo Finance • last year
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper... Full story
Yahoo Finance • last year
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as ap... Full story
Yahoo Finance • last year
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s... Full story
Yahoo Finance • last year
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effe... Full story
Yahoo Finance • last year
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open. Management will conduct... Full story
Yahoo Finance • last year
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA® (sotagliflozin) recently approved by FDA for treat... Full story
Yahoo Finance • last year
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved by FDA for treatment of heart failure... Full story
Yahoo Finance • last year
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Oct. 17, 2023 (GLOB... Full story
Yahoo Finance • last year
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care & Specialty Pharmacy (JMCP)... Full story
Yahoo Finance • last year
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE WOODLANDS, Texas, Oct. 09, 2023 (GLO... Full story
Yahoo Finance • last year
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.... Full story
Yahoo Finance • last year
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase 3 cardiovascular outcomes studies that led to FDA approval THE WOODLANDS, Texas, Sep... Full story
Yahoo Finance • last year
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain THE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lexico... Full story
Yahoo Finance • last year
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Conference, taking place September 11-13,... Full story
Yahoo Finance • last year
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end... Full story
